Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)

Summary

The current literature suggests that the mode of action of benralizumab is to deplete eosinophils through a mechanism of antibody-dependent cell-mediated cytotoxicity. This direct cellular cytotoxicity may not explain all of the benralizumab effects. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.

Timeline

Start

2023-04

Primary completion

2024-06

Completion

2025-01

Drugs

Indications